Nuvation Bio gets FDA Fast Track for safusidenib in glioma
Nuvation Bio says the FDA granted Fast Track designation for safusidenib in IDH1-mutant glioma, with pivotal Phase 3 Sigma study enrollment underway.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Nuvation Bio gets FDA Fast Track for safusidenib in glioma
Nuvation Bio says the FDA granted Fast Track designation to safusidenib for treatment of IDH1-mutant glioma.